Welcome to our dedicated page for Genmab A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S reported that worldwide net trade sales of DARZALEX (daratumumab), including the subcutaneous formulation DARZALEX FASPRO, were USD 4,207 million for the second quarter of 2026. Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.
Genmab receives royalties on these worldwide net sales of both intravenous and subcutaneous DARZALEX under an exclusive worldwide license granted to Johnson & Johnson’s Janssen Biotech to develop, manufacture and commercialize daratumumab. Genmab is an international biotechnology company focused on innovative antibody medicines for cancer and other serious diseases.
Genmab reported positive topline Phase 3 results from the EPCORE DLBCL-4 trial of epcoritamab plus lenalidomide in adults with relapsed or refractory diffuse large B-cell lymphoma. The combination, given as a fixed-duration, chemotherapy-free regimen, was compared with standard R-GemOx chemoimmunotherapy.
The study met its primary objective, showing a statistically significant and clinically meaningful improvement in progression-free survival. Depending on regional censoring rules, the risk of disease progression or death was reduced by 60% (HR 0.40; 95% CI 0.30–0.55) in the U.S. and 56% (HR 0.44; 95% CI 0.33–0.60) outside the U.S., both with p<0.0001.
The safety profile of epcoritamab plus lenalidomide was consistent with previously known profiles of each drug. Genmab and its partner AbbVie plan to engage global regulators and present detailed data at a future medical meeting, supporting epcoritamab’s potential broader role across B-cell malignancies.
Genmab A/S is making a very small capital increase by issuing 185 new shares following the exercise of employee warrants. The shares are subscribed in cash at DKK 1,334.50 per share, providing the company with approximately DKK 0.2 million in proceeds and representing less than 0.001% of its share capital.
After this increase, Genmab’s total nominal share capital is DKK 62,353,252, divided into 62,353,252 ordinary shares with one vote each. The new shares carry standard rights, including dividends from the date of subscription, and will be listed on Nasdaq Copenhagen once registered with the Danish Business Authority.
Genmab A/S reports a major shareholder status change for Orbis Investment Management Limited under Section 30 of the Danish Capital Markets Act. As of June 12, 2026, Orbis controls the voting rights to 3,112,476 Genmab shares, equal to 4.99% of the company’s share capital and voting rights.
The attached notification shows this holding decreased from 5.0783% of voting rights on a previous date. The Allan & Gill Gray Foundation is listed as the person subject to the notification obligation, with the Orbis group entities identified in the ownership chain.
Genmab A/S reports that its Board of Directors has granted 15,894 restricted stock units and 15,494 warrants to employees of the company and its subsidiaries. Each restricted stock unit is awarded cost-free, has a fair value equal to the DKK 1,616.50 closing share price on the grant date, and will vest after three years, subject to program conditions.
Each warrant is also awarded cost-free, carries an exercise price of DKK 1,616.50 per share and a calculated fair value of DKK 534.23 using the Black-Scholes formula. The warrants vest three years after grant and expire seven years after the grant date, under Genmab’s existing warrant program.
Genmab A/S filed a Form 6-K reporting insider trading activity by a managerial employee. Board member Michael Kavanagh sold 526 Genmab shares on May 29, 2026 on NASDAQ Copenhagen at a price of DKK 1,734.75 per share.
The filing is made under European Market Abuse Regulation Article 19 and is incorporated by reference into several of Genmab’s employee share plan registration statements on Form S-8. Genmab also reiterates its focus on antibody-based medicines and includes standard forward-looking statement risk disclosures.
Genmab A/S ownership disclosure: two institutional investors filed an amended Schedule 13G/A reporting beneficial ownership positions in Genmab common stock. The filing shows 3,557,484 shares beneficially owned representing 5.5% of the class and identifies Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd as the reporting persons.
The filing breaks the holdings down by voting and dispositive power: Orbis holds 3,549,674 shares with sole voting and dispositive power, and Allan Gray Australia holds 7,810 shares with sole voting and dispositive power. The filing states the reporting persons are non-U.S. institutions functionally equivalent to an investment adviser and disclaims group beneficial ownership.